Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form 4

INDEVUS PHARMACEUTICALS INC

Form 4

December 29, 2008

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

burden hours per

Estimated average response... 0.5

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

1(b).

value

(Print or Type Responses)

may continue.

See Instruction

1. Name and Address of Reporting Person ** BUTLER MARK S			2. Issuer Name and Ticker or Trading Symbol INDEVUS PHARMACEUTICALS					5. Relationship of Reporting Person(s) to Issuer			
			INC [IDEV]					(Check all applicable)			
(Last)	(First)	(Middle)		f Earliest T Day/Year)	ransaction			DirectorX Officer (give below)		Owner er (specify	
33 HAYDEN AVENUE			12/23/2008					Executive Vice President			
	(Street)		4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check				
	Filed(Month/Day/Year)					Applicable Line) _X_ Form filed by One Reporting Person					
LEXINGTO	ON, MA 02421								fore than One Re		
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Secu	rities Acqu	ired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)		2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Data any (Month/Day/Y		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price			ed of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, \$.001 par value	12/23/2008			A(2)	5,000	(D)	Price \$ 2.375	88,258	D		
Common Stock, \$.001 par	12/23/2008			D <u>(3)</u>	5,000	D	\$ 2.7668	83,258	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number opportunities Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amoun or Numbe of Shares
Employee Stock option (right to buy)	\$ 2.375	12/23/2008		M <u>(1)</u>	5,000	04/05/2001(1)	04/05/2010	Common Stock, \$.001 par value	5,000

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BUTLER MARK S 33 HAYDEN AVENUE LEXINGTON, MA 02421

Executive Vice President

Signatures

Mark S. Butler 12/29/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents exercise of stock option granted pursuant to the Company's 1994 Long-term Incentive Plan. This stock option is a portion of a stock option award that had incremental vesting and became fully exercisable on April 5, 2001.
- (2) Represents shares acquired from exercise of stock options granted pursuant to the Company's 1994 Long-term Incentive Plan.
- (3) Represents sale pursuant to a 10b5-1 Plan of common stock received following exercise of stock option as discussed in footnote 2.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2